Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Ezetimibe no cancer risk

Treatment with ezetimibe does not increase a patient's risk of cancer, according to a major study of its use when prescribed in combination with a statin.

A previous study – the SEAS trial – had found ezetimibe was associated with an increase in new-onset cancers. But researchers from the University of Oxford analysed data from three trials, including SEAS, on 22,490 patients prescribed three different dose combinations of ezetimibe and simvastatin for a total mean follow-up period of 7.8 years.

The risk of cancer with ezetimibe was 0.96, indicating no effect on cancer incidence.

N Engl J Med 2008:359.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say